| ABSTRACT | Volume 1, Issue 1, Pages 6-9 (March 2015)
| Safila Naveed | Zehra Ashraf and | Tanweer Alam Muhammad |. American Journal of Innovative Research and Applied Sciences. 2015; 1(1): 6-9.
| PDF FULL TEXT |
Background: Vildagliptin (VLD) is belonging to a new dipeptidyl peptidase-IV inhibitor class of drugs. VLD is an oral anti-diabetic drug (anti-hyperglycemic agent). The IUPAC formula of vildagliptin is
(2S)-1-[[(3-Hydroxytricyclo [220.127.116.11,7]dec-1-yl) amino]acetyl]-2-pyrrolidinecarbonitrile). Objectives: The purpose of this study was to carry out the pharmaceutical assay on different brands
(VILDOS, GALVIS and VILGLIP) of Vildagliptin, by Shimadzu double beam 1601 UV visible spectrophotometer at wavelength 266nm. Methods: Five dilutions of 200ppm, 100, 50, 25, 12 ppm for each
brand of Vildagliptin were prepared. Results: Results indications that absorbance is directly proportion to concentration thus, it is obeys to Beers lambert law and assay of all brands of Validagliptin.
We have performed these types of assay for different brand which helpful for selecting drugs. Conclusion: It shows a linear relationship between absorbance and concentration.
KEYWORDS: Vildagliptin, dipeptidyl peptidase-IV inhibitor, anti-diabetic drug.